Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Atossa Therapeutics Inc. (ATOS:NASDAQ), powered by AI.
Atossa Therapeutics Inc. is currently trading at $2.58. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Atossa Therapeutics Inc. on Alpha Lenz.
Atossa Therapeutics Inc.'s P/E ratio is -0.6.
“Atossa Therapeutics Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -62.7%.”
Ask for details →Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for breast cancer and other breast conditions. The primary aim of Atossa Therapeutics is to advance healthcare solutions through its proprietary therapies that target significant unmet medical needs related to breast health. Atossa develops both oral and topical treatments designed to improve outcomes and experiences for patients undergoing various stages of breast cancer treatment, as well as preventive measures for high-risk patients. One of the company's notable approaches involves utilizing molecular and genetic analysis to tailor personalized medicine. Atossa Therapeutics operates in the dynamic biotechnology sector, contributing to advancements in oncology, specifically in hormone receptor-positive and triple-negative breast cancers. Its research and development efforts hold potential implications for the pharmaceutical industry, offering novel therapeutic options that could enhance standards of care. Established in Seattle, Washington, Atossa continues to play a key role in the biopharmaceutical market by championing the development of targeted therapies, underscoring the importance of innovation in tackling complex health challenges.
“Atossa Therapeutics Inc. trades at a P/E of -0.6 (undervalued) with modest ROE of -62.7%.”
Ask for details →Atossa Therapeutics Inc. (ticker: ATOS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15 employees. Market cap is $22M.
The current price is $2.585 with a P/E ratio of -0.64x and P/B of 0.57x.
ROE is -62.74%.